Closely-held BioSight has completed patient treatment in its ongoing Phase 1/2a clinical study of Astarabine in acute leukemia patients and expects to report final results in coming months.
The Phase 1/2a trial is an open-label study to evaluate the safety and efficacy of Astarabine as single agent in adults with acute myeloid leukemia (AML) and relapsed/refractory acute lymphoblastic leukemia (ALL).
Results to date demonstrate safety in all patients, with no significant drug-related adverse events, including in patients aged 80 and 90 years old. In addition, Astarabine treatment has led to high response rates in newly diagnosed AML and ALL patients, as well as in secondary AML patients.
“We are looking forward to continuing the development of Astarabine to further evaluate and establish its safety and efficacy in a larger study,” CEO, Dr. Ruth Ben Yakar, said in a statement.
“We truly believe that Astarabine can bring hope to many patients and their families and provide an answer to unmet needs in the treatment of both AML and ALL,” she added.
